Subscribe To

Price Alert Latest News Economic Calendar News

CDNA / CareDx: Short-Term Headwinds Will Pass, Longer-Term High Growth Investment Case Remains

Although CareDx (CDNA) recently received inquiries from the DOJ and SEC, the longer-term investment case remains intact. CDNA has only begun to scratch the surface on its total market opportunity and the company is pursuing multiple growth strategies that should keep sales increasing at a high rate. Read More

Demo Live Account See Partner Details

Content Topics

Pacer

Benchmark

Industrial

Real

Estate

Sctr

Etf

Inds

Caredx

Short term

Headwinds

Longer term

Growth

Investment

Remains

Stock

CDNA

Posted: Jan 4 2022, 22:49

Author Name: Seeking Alpha

CDNA News

By Zacks Investment Research
August 8, 2023

CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

CareDx (CDNA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.13

By Zacks Investment Research
July 10, 2023

CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the st

By The Motley Fool
July 7, 2023

Why Shares of CareDx Are Jumping Friday

CareDx specializes in diagnostic testing for transplant patients. The company's revenue declined 3% year over year in the first quarter.

By Business Wire
May 8, 2023

CareDx to Report First Quarter 2023 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercializat

By Seeking Alpha
February 27, 2023

CareDx, Inc. (CDNA) Q4 2022 Results Earnings Call Transcript

CareDx, Inc. (NASDAQ:CDNA ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Greg Chodaczek - IR Reginald Seeto - CE

By Zacks Investment Research
February 27, 2023

CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold cl

By Seeking Alpha
December 12, 2022

CareDx: What To Make Of The New Share Repurchase Program (Rating Upgrade)

CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions

By Seeking Alpha
November 3, 2022

CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2022 Results - Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhis

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.